How stimulant drugs affect risky choice and the role of reinforcement magnitude has been an important question for research on impulsivity. This study investigated rats' responding on a rapid acquisition, concurrent chains, probability discounting task under methamphetamine administration. In each block of four sessions, probability of reinforcement delivery was unequal (0.5/1.0, 1.0/0.5) or equal, (1.0/1.0, 0.5/0.5) while amount of reinforcement was constant and unequal. This allowed for an estimate of probability discounting and the magnitude effect (where larger reinforcers are discounted at a greater rate) in each block. Baseline, acute and chronic methamphetamine administration, and re-establish baseline phases were completed. Rats showed sensitivity to probability and magnitude in baseline, as well as a magnitude effect whereby preference for the larger reinforcement was greater with 100% than 50% reinforcement probability. Acute methamphetamine dose-dependently reduced the probability effect. There were no effects of chronic administration and only probability discounting was maintained in the re-establish baseline phase. This was the first procedure to find a magnitude effect with rats in a probability discounting procedure and demonstrates that acute methamphetamine reduces both the probability and magnitude effects which increases propensity for risky choice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.beproc.2023.104971 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.
J Manag Care Spec Pharm
January 2025
Abbott Diabetes Care, Mississauga, Ontario, Canada.
Background: Both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and continuous glucose monitoring (CGM) have been shown to improve glycated hemoglobin A1c (A1c) levels among patients with type 2 diabetes mellitus (T2DM). Recently, a US real-world study found statistically significant improvements in A1c levels among patients using GLP-1 RA and a CGM device, compared with a matched cohort receiving only GLP-1 RA.
Objectives: To assess the cost-effectiveness from a US payer perspective of initiating CGM (FreeStyle Libre Systems) in people living with T2DM using a GLP-1 RA therapy, compared with GLP-1 RA alone.
Understanding Cancer Treatment Decision Making Among Cancer Survivors: Weighing Cancer Recurrence Versus Cardiotoxicity.
Psychooncology
January 2025
Integrative Biological and Behavioral Sciences, Division of Extramural Scientific Programs, National Institute on Minority Health and Health Disparities, Rockville, Maryland, USA.
Background: Nearly 20% of US cancer survivors develop cardiovascular disease (CVD) from cardiotoxic cancer treatments. Patients and providers may consider alternative treatments to lower cardiotoxicity risk, but these may be less effective at preventing relapse/recurrence, presenting a difficult tradeoff.
Aims: This study explored survivors' cancer treatment decision-making when weighing this tradeoff.
Clinical outcomes and cost-utility analysis of GKRS plus TKIs versus TKIs in patients with EGFR-mutant lung adenocarcinoma and brain metastases: a Markov decision model.
J Neurosurg
January 2025
8Department of Healthcare Administration and Medical Informatics, Kaohsiung Medical University, Kaohsiung.
Objective: This study focuses on epidermal growth factor receptor-mutated lung adenocarcinoma, known for frequent brain metastasis. It aimed to compare the clinical outcomes and cost-effectiveness of combining Gamma Knife radiosurgery (GKRS) with tyrosine kinase inhibitors (TKIs) (GKRS+TKI group) versus TKIs alone (TKI group) for the treatment of patients with newly diagnosed brain metastasis in this condition.
Methods: Study characteristics of the two groups were matched using inverse probability of treatment weighting (IPTW).
Botulinum toxin type A for the treatment of patients with post-stroke spasticity in Thailand: cost-utility and budget impact analysis.
BMJ Open
January 2025
Siriraj Health Policy Unit, Mahidol University Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
Objectives: To evaluate the cost-utility of botulinum toxin A (BoNT-A) for treating upper limb (UL) and lower limb (LL) post-stroke spasticity.
Design: Using a Markov model, adopting a societal perspective and a lifetime horizon with a 3% annual discount rate, the cost-utility analysis was conducted to compare BoNT-A combined with standard of care (SoC) with SoC alone. Costs, utilities, transitional probabilities and treatment efficacy were derived from 5-year retrospective data from tertiary hospitals and meta-analysis.
Impact and cost-effectiveness of scaling up HCV testing and treatment strategies for achieving HCV elimination among people who inject drugs in England: a mathematical modelling study.
Lancet Reg Health Eur
February 2025
Bristol Medical School, University of Bristol, Bristol, UK.
Background: England aims to reach the World Health Organization (WHO) elimination target of decreasing HCV incidence among people who inject drugs (PWID) to <2 per 100 person-years (/100pyrs) by 2030. We assessed what testing and treatment strategies will achieve this target and whether they are cost-effective.
Methods: A dynamic deterministic HCV transmission model among PWID was developed for four England regions, utilising data on the scale-up of HCV treatment among PWID in prisons, drug treatment centres (DTC, where opioid agonist therapy is provided), and any other setting (e.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!